Igm Biosciences, Inc. SEC Filings

IGM Biosciences completed a merger and terminated its Form S-8 offerings. Under a Merger Agreement dated July 1, 2025, the company merged into a subsidiary of Concentra Biosciences and became a wholly owned subsidiary of Parent on August 14, 2025. Each outstanding public share (with limited exceptions) converted into $1.247 in cash plus one non-transferable contractual contingent value right (CVR) per share. As a result, the registrant terminated all offerings under the referenced Form S-8 registration statements and filed post-effective amendments to withdraw and remove any unissued and unsold securities from registration.

IGM Biosciences has filed post-effective amendments to withdraw all unissued and unsold shares previously registered under multiple Form S-8 registration statements because the company completed a merger on August 14, 2025. Under the Merger Agreement, IGM became a wholly owned subsidiary of Concentra Biosciences, LLC; each outstanding common share (other than specified exceptions) was converted into $1.247 in cash and one non-transferable contractual contingent value right (CVR). As a result, the registrant terminated the planned securities offerings and removed remaining registered but unsold securities from registration.

IGM Biosciences, Inc. filed a Form 25 notifying the removal of its common stock from listing and/or registration on the Nasdaq Stock Market LLC. The filing includes statements that Nasdaq has complied with 17 CFR 240.12d2-2(b) and that the issuer has complied with 17 CFR 240.12d2-2(c) governing voluntary withdrawal. The document is signed by Tara Petta, AVP and dated 2025-08-14. The filing does not disclose an effective date for removal, the specific rule provision selected on the form, or the underlying reasons for the removal.

IGM Biosciences, Inc. amended its Schedule 14D-9 to report the final results of the tender offer by Concentra Biosciences, LLC. The Offer expired at one minute after 11:59 p.m., Eastern time, on August 13, 2025, and Broadridge advised Parent that 28,373,092 voting Shares were validly tendered and not validly withdrawn, representing approximately 77.53% of voting Shares outstanding at expiration. The tender satisfied the Minimum Tender Condition and all other Offer conditions were satisfied or waived. Parent accepted for payment all validly tendered Shares and expects to promptly pay the Offer Price of $1.247 per Share in cash plus one non-transferable contractual contingent value right (CVR). Pursuant to the Merger Agreement and Section 251(h) of the DGCL, Parent completed the Merger on August 14, 2025; outstanding Shares (with specified exceptions) were cancelled and converted into the right to receive the Offer Price, Shares ceased trading prior to Nasdaq open on August 14, 2025, and will be delisted and deregistered under the Exchange Act.

IGM Biosciences (IGMS) Form 4: CFO Misbah Tahir disclosed the sale of 8,741 common shares on 07/23/2025 at a weighted-average price of $1.2728 per share. The transaction was executed in multiple trades within a $1.27–$1.275 range and was explicitly undertaken to cover tax-withholding obligations associated with vesting restricted stock units (RSUs).

Following the sale, Tahir’s direct beneficial ownership stands at 170,061 shares. No derivative security transactions or additional acquisitions were reported. The filing represents a routine insider sale rather than a strategic disposition, and no other material events or financial metrics are included.